Biomedical Sector

The Tangs Family Investment is strategically focused on the biomedical sector and gene therapy, investing in companies that are at the forefront of medical innovation.

Within the biomedical sector, the investment targets firms involved in biopharmaceuticals, medical devices, and diagnostics, with a strong emphasis on breakthrough treatments and technologies addressing critical healthcare challenges.

• Biomedical Sector Focus:

  • The Tangs Family Investment is particularly interested in companies advancing biopharmaceutical research, including those developing immunotherapies, monoclonal antibodies, and next-generation vaccines.

  • The fund also invests in medical device companies creating innovative solutions for diagnostics, patient monitoring, and minimally invasive procedures, driving efficiency and improving patient outcomes.

  • It seeks out firms working on precision medicine, which tailors treatments based on genetic, environmental, and lifestyle factors, aligning with the broader goal of personalized healthcare.

  Gene Therapy Focus:

  • A core focus of the fund is on gene therapy companies, which are revolutionizing the treatment of genetic disorders by targeting the underlying causes of disease at the DNA level.

  • The Tangs Family Fund supports businesses developing therapies that utilize CRISPR technology, viral vectors, and cell-based therapies to treat or potentially cure conditions like inherited genetic disorders, cancer, and neurological diseases.

  • Investments are made in firms conducting clinical trials and developing pipelines for FDA approvals, aiming to bring these groundbreaking therapies to market.